Review the trend for a client receiving elacestrant and select the best interpretation and action.
Trend
Choose your responses, then check the answer.
Explanation
Progressive hypercholesterolemia and hypertriglyceridemia require follow-up, and a newly added moderate or strong CYP3A4 inhibitor creates an avoidable interaction that can increase elacestrant exposure.
Quick answer Connect the lipid trend and new CYP3A4 inhibitor to an elacestrant safety review.
Why this is correct Elacestrant requires lipid assessment before and during therapy. Strong or moderate CYP3A4 inhibitors and inducers should be avoided, so the new interacting prescription must be clarified before another dose.
Easy analogy or mental picture Build a medication-safety chain: identify the changing cue, connect it to the labeled toxicity or interaction, interrupt preventable exposure, stabilize the client, and verify a measurable response.
NCLEX decision rule Choose the action that prevents the most immediate medication-related harm while preserving indicated treatment and required monitoring.
Why the other choices are wrong Options that continue a suspect exposure, normalize a labeled danger cue, or delay escalation leave the client at risk.
References
1DailyMed: ORSERDU (elacestrant)Lipid monitoring, CYP3A4 inhibitor and inducer avoidance, hepatic impairment, and embryo-fetal risk counseling
Oncology medication-safety reviewVerify indication, current assessment, laboratory and oxygen trends, interactions, urgent toxicity cues, authorized action, and measurable follow-up.